Lindbrook Capital LLC Decreases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Lindbrook Capital LLC cut its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 34.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 336 shares of the company’s stock after selling 175 shares during the quarter. Lindbrook Capital LLC’s holdings in TransMedics Group were worth $27,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Global Retirement Partners LLC purchased a new position in shares of TransMedics Group in the third quarter valued at $38,000. Cutler Group LLC CA grew its position in shares of TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares in the last quarter. RiverPark Advisors LLC purchased a new position in shares of TransMedics Group in the third quarter valued at $60,000. Van ECK Associates Corp grew its position in shares of TransMedics Group by 39.0% in the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock valued at $116,000 after purchasing an additional 597 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of TransMedics Group in the third quarter valued at $180,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMDX has been the subject of several recent research reports. Piper Sandler started coverage on TransMedics Group in a research report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price target for the company. Oppenheimer lifted their price objective on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. Morgan Stanley lifted their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Finally, JPMorgan Chase & Co. lifted their price objective on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.00.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $92.08 on Friday. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The business has a 50-day moving average price of $82.98 and a two-hundred day moving average price of $74.53. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $99.63.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million during the quarter, compared to analyst estimates of $68.49 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company’s revenue was up 158.6% compared to the same quarter last year. Research analysts predict that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 7,157 shares of TransMedics Group stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total transaction of $618,221.66. Following the completion of the sale, the director now owns 8,350 shares of the company’s stock, valued at $721,273. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Stephen Gordon sold 15,000 shares of TransMedics Group stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $85.45, for a total value of $1,281,750.00. Following the transaction, the chief financial officer now owns 13,075 shares in the company, valued at $1,117,258.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Edward M. Basile sold 7,157 shares of TransMedics Group stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the transaction, the director now owns 8,350 shares in the company, valued at approximately $721,273. The disclosure for this sale can be found here. Insiders sold a total of 117,078 shares of company stock valued at $9,972,971 over the last 90 days. Insiders own 6.70% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.